

5<sup>th</sup> July, 2021

<b>BSE Limited</b> Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001  <b><u>Scrip Code: 532300</u></b>	<b>National Stock Exchange of India Limited</b> Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051  <b><u>NSE Symbol – WOCKPHARMA</u></b>
---	---

Dear Sir/ Madam,

**Sub: Press Release**

Please find enclosed herewith proposed Press Release titled “**Wockhardt UK proudly hosts visit of HRH The Prince of Wales**”

Kindly take the above information on record.

Thanking you,

For **Wockhardt Limited**



**Gajanand Sahu**  
**Company Secretary**

Encl: As above



Mumbai, 5<sup>th</sup> July, 2021

## **Wockhardt UK proudly hosts visit of HRH The Prince of Wales**

Global pharmaceutical company Wockhardt UK, which has reserved capacity to allow for the supply of multiple vaccines to the UK government in its fight against COVID-19, was delighted to welcome His Royal Highness The Prince of Wales (Prince Charles) to its Wrexham manufacturing facility.

Wockhardt UK specialises in the manufacture of sterile injectables and is one of the largest generic pharmaceutical companies in the UK with the capability to manufacture on a large-scale. Wockhardt is one of the major suppliers to the NHS and has had a site in Wrexham for over 20 years. It employs more than 500 people at the 612,000 sq. ft. high-tech factory.

While acknowledging the visit as a mark of honour, the Founder Chairman of Wockhardt Dr. Habil Khorakiwala said, "The visit today by His Royal Highness The Prince of Wales demonstrates recognition of our global strength in sterile injectable facilities and capacity. With four decades of expertise and experience behind us, we have been able to quickly rise to the occasion, scale up the manufacture of the vaccines and assist in mitigating the worldwide impact of COVID-19."

Wockhardt UK has been instrumental in the manufacture of the Oxford/AstraZeneca COVID-19 vaccine and carries out the 'fill and finish' stage of the vaccine manufacturing process. The firm has a manufacturing contract with the UK Government in place until August 2022. This involves dispensing the COVID-19 vaccine into vials ready for it to be sent out across the country.

The visit comes eight months after Wockhardt welcomed Prime Minister Boris Johnson, who thanked staff for their hard work, saying that the vaccines could provide the "salvation for humanity."

Dr. Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt adds, "We are delighted to showcase our innovation, talent and expertise at Wockhardt UK to His Royal Highness. We are committed to the cause and can be a key partner globally in fighting the world's most demanding need of the hour during COVID-19."

Ravi Limaye, Managing Director Wockhardt UK said, "It is a great honour to have His Royal Highness The Prince of Wales visit us today. We have been working at pace to ensure that our sophisticated sterile facility and our highly skilled workforce are geared up to manufacture the vaccines which have already been widely distributed to people across the UK."

"To have His Royal Highness here to witness the pride and purpose of the Wockhardt team in Wrexham means so much to everyone."

### **About Wockhardt:**

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over 5000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.

Wockhardt UK specialises in the supply of generic and speciality medicines and is one of the leading suppliers to the NHS. They have a portfolio of over 250 product lines which are available in a wide range of preparations, including tablets, capsules, injections and liquid medicines.

The UK manufacturing site based in Wrexham, North Wales manufactures a number of sterile injectable products covering a wide range of therapy areas including diabetes, anticoagulation and pain management. The products are available in many forms such as vials, cartridges and ampoules including lyophilised (dry powder) products. In addition to their own Wockhardt branded products, they also provide contract manufacturing services for companies all around the world.